VentureMed Group develops and commercializes endovascular technologies that address peripheral arterial disease (PAD) and arteriovenous fistula and graft (AVF/AVG) interventions. Its flagship product, the FDA 510(k)-cleared and CE-Mark–approved FLEX Vessel Prep™ System, employs Kinetic Endovascular Micro-incision Creation (KEMIC) to create precise micro-incisions, enhancing luminal gain, drug uptake, and long-term vessel patency while minimizing trauma. The device already carries a dedicated CMS HCPCS code (C1600) with transitional pass-through payment, positioning it for broader U.S. adoption. VentureMed plans to use newly raised capital to expand its commercial infrastructure, generate additional clinical evidence, and pursue new indications in adjacent vascular settings. Global market demand is driven by more than 20 million U.S. PAD patients and widespread dialysis-related access issues. The company remains privately held and has attracted repeat backing from institutional investors, most recently closing a $28 million Series C round to fund growth and product development.

Total raised

$43M

Funding rounds

2

Latest round

Series C

Latest activity

Oct 2025